RVMD vs. EXEL, PCVX, IBRX, HALO, CRSP, KRYS, IMVT, IOVA, RGEN, and QGEN
Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include Exelixis (EXEL), Vaxcyte (PCVX), ImmunityBio (IBRX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), Immunovant (IMVT), Iovance Biotherapeutics (IOVA), Repligen (RGEN), and Qiagen (QGEN). These companies are all part of the "biological products, except diagnostic" industry.
Revolution Medicines (NASDAQ:RVMD) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.
94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 8.5% of Revolution Medicines shares are owned by company insiders. Comparatively, 2.9% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Exelixis received 513 more outperform votes than Revolution Medicines when rated by MarketBeat users. However, 68.82% of users gave Revolution Medicines an outperform vote while only 68.20% of users gave Exelixis an outperform vote.
Exelixis has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Revolution Medicines and Revolution Medicines both had 16 articles in the media. Revolution Medicines' average media sentiment score of 0.73 beat Exelixis' score of 0.04 indicating that Revolution Medicines is being referred to more favorably in the media.
Revolution Medicines has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.
Exelixis has a net margin of 11.10% compared to Revolution Medicines' net margin of 0.00%. Exelixis' return on equity of 8.85% beat Revolution Medicines' return on equity.
Revolution Medicines currently has a consensus price target of $41.60, indicating a potential upside of 11.56%. Exelixis has a consensus price target of $26.33, indicating a potential upside of 21.97%. Given Exelixis' higher possible upside, analysts clearly believe Exelixis is more favorable than Revolution Medicines.
Summary
Exelixis beats Revolution Medicines on 10 of the 18 factors compared between the two stocks.
Get Revolution Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revolution Medicines Competitors List
Related Companies and Tools
